A Pilot Study to Investigate the Potential of Buparid/PARI SINUS Versus Budes Nasal Spray to Avoid or Postpone Sinus Surgery in Adult Patients With Chronic Rhinosinusitis
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 25 Jan 2019
Price : $35 *
At a glance
- Drugs Budesonide (Primary) ; Budesonide (Primary)
- Indications Rhinosinusitis
- Focus Adverse reactions; Therapeutic Use
- Sponsors PARI Pharma GmbH
- 03 Apr 2018 Planned End Date changed from 1 May 2018 to 1 Jan 2019.
- 03 Apr 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Nov 2018.
- 12 Dec 2017 Status changed from recruiting to active, no longer recruiting.